B. Nordlinger
Annals of Oncology · 2006–2017
A researcher in the Science corpus: 9 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Who trusts B. Nordlinger overall
Papers from B. Nordlinger's perspective
Ordered by how strongly the researchers B. Nordlinger trusts endorse each paper. Same corpus, a different order for every researcher.
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. (The Lancet Oncology)
- Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (Journal of Clinical Oncology)
- PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated,… (Journal of Clinical Oncology)
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. (The Lancet Oncology)
- Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroœsophageal junction
- Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. (New England Journal of Medicine)
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (New England Journal of Medicine)
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (Annals of Oncology)
- K-ras mutations and benefit from cetuximab in advanced colorectal cancer. (New England Journal of Medicine)
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
Their papers
- Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial (2017) — 634 citations
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) — 1,102 citations
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) — 882 citations
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. (2013) — 1,113 citations
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012) — 1,471 citations
- Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. (2010) — 666 citations
- Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. (2010) — 1,156 citations
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial (2008) — 1,860 citations
- Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases (2006) — 728 citations